Answers are grounded in this paper and cite their sources.
Guselkumab is a monoclonal antibody approved for treating moderate-to-severe plaque psoriasis. Long-term data on the effectiveness and safety of guselkumab in a real-world setting are still limited.
No takes yet. Share an insight, caveat, or question.
Gargiulo et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: